» Articles » PMID: 29552193

Effect of HK2, PKM2 and LDHA on Cetuximab Efficacy in Metastatic Colorectal Cancer

Overview
Journal Oncol Lett
Specialty Oncology
Date 2018 Mar 20
PMID 29552193
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Although hexokinase (HK) 2, pyruvate kinase muscle (PKM) isozyme 2 and lactate dehydrogenase (LDH) A predict the efficacy of medicines in various solid tumors, their ability to predict the efficacy of cetuximab in metastatic colorectal cancer (mCRC) remains unclear. mCRC patients with pathological specimens who received cetuximab and chemotherapy from 2005 to 2015 in the present institution were enrolled. Immunohistochemistry was used to detect HK2, PKM2 and LDHA expression. SPSS20 was used for statistical analysis. A total of 68 patients were included; 33 received cetuximab plus chemotherapy as first-line therapy, and the rest, as second- or later-line therapy. HK2 expression levels were increased in cancer compared with normal tissue (75.4% vs. 40%; P<0.001), however PKM2 (P=0.243) and LDHA (P=0.067) expression levels were not. For progression-free survival (PFS) with first-line cetuximab plus chemotherapy, patients with high HK2 expression exhibited longer PFS compared with those with low HK2 expression (23.9 months vs. 6.9 months; P=0.021). However, this positive association was absent in 35 cases administered first-line chemotherapy alone (13.4 months vs. 13.5 months; P=0.539). LDHA expression was associated with the PFS of patients receiving first-line chemotherapy (18.3 and 10.1 months for high and low expression, respectively; P=0.005), whereas this association was absent in cetuximab plus chemotherapy cases (19.9 months vs. 12 months; P=0.522). Furthermore, high LDHA expression correlated with high overall response rate (ORR) (72.2% vs. 15.4%, P=0.006) for chemotherapy, however not disease control rate (DCR) (P=0.074). Neither DCR nor ORR were associated with HK2 expression. PKM2 expression did not affect PFS, DCR or ORR. LDHA expression (P=0.005), pathological differentiation (P=0.019) and synchronous/metachronous metastasis (P=0.014) were independent predictive factors of PFS for all first-line patients, and tumor differentiation (P=0.002) was associated with overall survival (OS) in multivariate analysis. HK2, PKM2 and LDHA did not impact OS. It was concluded that HK2 expression was increased in colorectal cancer tissue and may predict cetuximab efficacy and LDHA for chemotherapy treatment of mCRC.

Citing Articles

Exploring the Link Between Noncoding RNAs and Glycolysis in Colorectal Cancer.

Xu L, Shen Y, Zhang C, Shi T, Sheng X J Cell Mol Med. 2025; 29(4):e70443.

PMID: 39993964 PMC: 11850098. DOI: 10.1111/jcmm.70443.


Harnessing Drug Repurposing to Combat Breast Cancer by Targeting Altered Metabolism and Epithelial-to-Mesenchymal Transition Pathways.

Kandasamy T, Sarkar S, Ghosh S ACS Pharmacol Transl Sci. 2024; 7(12):3780-3794.

PMID: 39698277 PMC: 11650739. DOI: 10.1021/acsptsci.4c00545.


CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration.

Geng Y, Zheng X, Zhang D, Wei S, Feng J, Wang W Biol Direct. 2024; 19(1):36.

PMID: 38715141 PMC: 11075259. DOI: 10.1186/s13062-024-00478-x.


Role of long non-coding RNAs in metabolic reprogramming of gastrointestinal cancer cells.

Wang K, Lu Y, Li H, Zhang J, Ju Y, Ouyang M Cancer Cell Int. 2024; 24(1):15.

PMID: 38184562 PMC: 10770979. DOI: 10.1186/s12935-023-03194-0.


Oncogenic Alterations of Metabolism Associated with Resistance to Chemotherapy.

Ghasemi F, Farkhondeh T, Samarghandian S, Ghasempour A, Shakibaie M Curr Mol Med. 2023; 24(7):856-866.

PMID: 37350008 DOI: 10.2174/1566524023666230622104625.


References
1.
Hamabe A, Yamamoto H, Konno M, Uemura M, Nishimura J, Hata T . Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1α in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis. Cancer Sci. 2014; 105(9):1100-8. PMC: 4462394. DOI: 10.1111/cas.12487. View

2.
Koukourakis M, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter K . Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003; 89(5):877-85. PMC: 2394471. DOI: 10.1038/sj.bjc.6601205. View

3.
Zhang Z, Feng X, Chen H, Duan Z, Wang L, Yang D . Prognostic significance of synergistic hexokinase-2 and beta2-adrenergic receptor expression in human hepatocelluar carcinoma after curative resection. BMC Gastroenterol. 2016; 16(1):57. PMC: 4891884. DOI: 10.1186/s12876-016-0474-8. View

4.
Patra K, Wang Q, Bhaskar P, Miller L, Wang Z, Wheaton W . Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013; 24(2):213-228. PMC: 3753022. DOI: 10.1016/j.ccr.2013.06.014. View

5.
Weihua Z, Tsan R, Huang W, Wu Q, Chiu C, Fidler I . Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 2008; 13(5):385-93. PMC: 2413063. DOI: 10.1016/j.ccr.2008.03.015. View